Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. Additionally, combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated potential benefits for patients with psoriasis and obesity, including improved immunometabolic health. The data reinforce Lilly's commitment to advancing treatments for chronic skin and metabolic conditions, with ongoing studies in pediatric populations and real-world settings. These findings could influence future treatment protocols and patient outcomes in dermatology and obesity management.
Eli Lilly's stock is trading at USD 1,140.80 on Pluang, showing a slight decline of 0.18% as of Oct 05, 2026 19:02 WIB. The company holds a strong market cap of $1.02 trillion, reflecting its significant presence in the health sector.
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achi...
